Conclusions
Patients with cirrhosis have a higher incidence of thrombosis and
bleeding events than healthy individuals, and patients requiring
anticoagulation therapy are at a high risk of bleeding. In the treatment
of PE, NOACs were found not inferior to VKAs. In addition, according to
the pooled data, NOACs caused a lower risk of bleeding than VKAs.
Furthermore, NOACs are not significantly affected by food, thus it may
be more suitable for patients with pulmonary embolism and fatty liver.